We work exclusively in behavioral health — mental health, substance use disorder, eating disorders, dual diagnosis, IOP/PHP, and adjacent outpatient services. This is the industry our founder came up through, from direct patient care to VP-level business development inside a hospital system. We focus where we have operational depth.

Selectively, in adjacent healthcare services like senior care and home health — primarily through warm referrals from existing relationships. For industries beyond healthcare, we'll tell you if we're not the right fit and may make an introduction where appropriate.

Structured exclusivity by sub-segment, geography, deal size, or target type — defined in writing in each engagement letter. We disclose category-level conflicts transparently at engagement start. We do not run parallel engagements targeting the same profile for competing acquirers.

Retainer-based, six-month minimum, with an optional success fee component on closed transactions. We maintain a limited client roster to ensure quality of attention — typically no more than two to three active platform engagements at any time. This is not a volume business.

We screen for clinical fit, operational health, payer mix, regulatory posture, leadership culture, and quality indicators — not just financial fit. A target that passes financial screens but fails clinical or cultural screens is not introduced. Our founder spent years in direct patient care and VP-level business development; that background produces a diligence filter most BD consultants cannot replicate.

No.

APS does not operate as a broker, intermediary, or transaction marketplace. We do not shop deals, represent sellers, or take commissions based on introductions. Our work is infrastructure-driven and platform-level — we build origination systems, not transaction pipelines.

Lead generation firms deliver activity.
APS builds ownership.

We don't sell ads, outbound lists, or short-term outreach campaigns. We build proprietary systems — market mapping, founder relationship development, pre-qualification on clinical and operational fit, and CRM/pipeline workflows — that platforms own and that survive leadership changes and exits.

No.

We build infrastructure that increases consistency, control, and scalability of deal origination. Outcomes depend on market conditions, execution, and capital alignment — factors no origination firm can guarantee. We do not promise deal volume or timelines.

In most cases, yes.

Exclusivity is structured by sub-segment, geography, deal size, or target type — defined in writing in each engagement letter. We do not run parallel engagements targeting the same profile for competing acquirers. Category-level conflicts are disclosed transparently at engagement start.

All engagements begin with a platform-level assessment.

This allows both sides to determine:

• Strategic fit — is the acquirer's thesis aligned with our origination approach?
• Scope — sub-segment, geography, deal size, and target profile
• Readiness — whether infrastructure, not lead generation, is the right solution

Not all conversations progress beyond this stage.